In vivo evaluation of the HeartWare centrifugal ventricular assist device

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Medical Device Technology

Background:

• Left ventricular assist devices (LVADs) are critical for managing advanced heart failure.
• Evaluating the long-term hemocompatibility and end-organ impact of implantable devices is essential.
• The HeartWare HVAD is a centrifugal pump used for mechanical circulatory support.

Purpose of the Study:

• To assess the 90-day hemocompatibility of the HeartWare HVAD in a healthy sheep model.
• To evaluate potential end-organ effects, specifically on the kidneys and liver, during long-term LVAD support.
• To determine the reliability and safety profile of the HeartWare HVAD without anticoagulation or antiaggregation therapy.

Main Methods:

• Implantation of the HeartWare HVAD into the left ventricular apex of 6 healthy sheep.
• Continuous monitoring of pump function and collection of hematologic/biochemical data for 90 days.
• Macroscopic and histopathological examination of end-organs post-explantation.

Main Results:

• The HeartWare HVAD exhibited exceptional hemocompatibility and reliability over the 90-day study period.
• Hematologic and biochemical parameters remained within normal limits, indicating no significant systemic adverse effects.
• No significant device failure or thrombus formation was observed in the pump's inflow/outflow conduits. Minor renal infarction occurred in two sheep.

Conclusions:

• The HeartWare HVAD demonstrates promising hemocompatibility and reliability for long-term use in a preclinical setting.
• The device's performance suggests a favorable safety profile, with minimal impact on major organs.
• These findings support the clinical potential of the HeartWare HVAD for patients with heart failure requiring mechanical support.